Lung Cancer Trials Ask AI to find trials
RecruitingPhase 1NCT06598306
Official study title

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

Study summary

The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.

Ask AI to explain this study
Start here

Key things to know

Main goalBasic Science

This describes the study’s primary purpose.

What is being studiedTarlatamab

The study team can explain what participation involves.

Who it may be forSmall cell lung cancer (SCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 26, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 1

Interventional

Where is it offered?31 U.S. locations

Locations may change over time.

Who runs it?Amgen

Study sponsor

01
Study overview

What this study is about

Purpose
Basic Science
Study type
Interventional
Phase
Phase 1
Sponsor
Amgen
Interventions being studied
Drug: Tarlatamab
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Small cell lung cancer (SCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Participants ≥ 18 years of age (or ≥ legal adult age within country if it is older than 18 years) at time of signing informed consent.
  • Participants with histologically or cytologically confirmed ES-SCLC that progressed or recurred following at least one line of platinum-based anti-cancer therapy for SCLC. Note: Participants with prior treatment for LS-SCLC should have also received another regimen for their recurrent, ES-SCLC disease.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.
  • Participants must have adequate organ function (cardiac, pulmonary, kidney, and liver).
  • Participants must be able to have SC injections administered in the abdomen.
  • Participants without measurable disease or tumor tissue (fresh biopsy or archival) available may be permitted after discussion with and approval by Amgen Medical Monitor.
Reasons someone may not be able to joinExclusion criteria
  • Participants that have received prior DLL3 targeted therapy.
  • Participants with untreated or symptomatic brain metastases or those requiring therapy with steroids.
  • Note: Participants with asymptomatic brain metastatic lesions are allowed following definitive treatment (Amgen Medical Monitor may approve untreated, asymptomatic brain metastasis if local therapy is not required per investigator judgment).
  • Participants with leptomeningeal disease.
  • Participants with baseline oxygen requirement.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of Southern California, Norris Comprehensive Cancer CenterLos Angeles, California
  • University of Illinois ChicagoChicago, Illinois
  • Trinity Health Saint Joseph Mercy Ann ArborAnn Arbor, Michigan
  • Avera Cancer InstituteSioux Falls, South Dakota
  • University of Texas MD Anderson Cancer CenterHouston, Texas
  • Swedish Cancer InstituteSeattle, Washington
  • Chris OBrien LifehouseCamperdown, New South Wales
  • Calvary Mater Newcastle HospitalWaratah, New South Wales
  • The Alfred HospitalMelbourne, Victoria
  • Universitair Ziekenhuis GentGhent
  • Universitair Ziekenhuis Leuven - Campus GasthuisbergLeuven
  • Centre Hospitalier Universitaire de Liege - Sart TilmanLiège

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 26, 2026. Always confirm current availability with the study team.

View original record ↗